Generic Rinvoq Availability
Last updated on Jan 11, 2023.
Rinvoq is a brand name of upadacitinib, approved by the FDA in the following formulation(s):
RINVOQ (upadacitinib - tablet, extended release;oral)
-
Manufacturer: ABBVIE INC
Approval date: August 16, 2019
Strength(s): 15MG [RLD] -
Manufacturer: ABBVIE INC
Approval date: January 14, 2022
Strength(s): 30MG [RLD] -
Manufacturer: ABBVIE INC
Approval date: March 16, 2022
Strength(s): 45MG [RLD]
Has a generic version of Rinvoq been approved?
No. There is currently no therapeutically equivalent version of Rinvoq available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rinvoq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 10,202,393
Issued: February 12, 2019
Assignee(s): AbbVie Inc.The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
Patent 10,344,036
Issued: July 9, 2019
Assignee(s): AbbVie Inc.The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 10,519,164
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 10,550,126
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 10,597,400
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 10,730,883
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 10,981,923
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 10,981,924
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 10,995,095
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 11,186,584
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 11,198,697
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 11,365,198
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Patent 11,512,092
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036✓
- October 17, 2036✓
- October 17, 2036
-
Tricyclic compounds
Patent 8,962,629
Issued: February 24, 2015
Assignee(s): AbbVie Inc.The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Patent expiration dates:
- January 15, 2031✓✓
- January 15, 2031✓✓
- January 15, 2031✓✓
- January 15, 2031✓✓
- January 15, 2031
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 9,951,080
Issued: April 24, 2018
Assignee(s): AbbVie Inc.The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓✓
- October 17, 2036
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
Patent 9,963,459
Issued: May 8, 2018
Assignee(s): AbbVie Inc.The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Tricyclic compounds
Patent RE47221
Issued: February 5, 2019
Assignee(s): AbbVie Inc.The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
Patent expiration dates:
- December 1, 2030✓
- December 1, 2030
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 16, 2024 - NEW CHEMICAL ENTITY
- December 14, 2024 - TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
- January 14, 2025 - TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, INCLUDING BIOLOGICS, OR WHEN USE OF THOSE THERAPIES AR
- March 16, 2025 - TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
- April 29, 2025 - TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
More about Rinvoq (upadacitinib)
- Check interactions
- Pricing & coupons
- Reviews (85)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antirheumatics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.